Results 11 to 20 of about 37,305 (235)

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX [PDF]

Haematologica, 2018
In the POLLUX study, daratumumab plus lenalidomide/dexamethasone significantly reduced risk of progression/death versus lenalidomide/dexamethasone alone in relapsed/refractory multiple myeloma.
Meletios A. Dimopoulos, Jesus San-Miguel, Andrew Belch, Darrell White, Lotfi Benboubker, Gordon Cook, Merav Leiba, James Morton, P. Joy Ho, Kihyun Kim, Naoki Takezako, Philippe Moreau, Jonathan L. Kaufman, Heather J. Sutherland, Marc Lalancette, Hila Magen, Shinsuke Iida, Jin Seok Kim, H. Miles Prince, Tara Cochrane, Albert Oriol, Nizar J. Bahlis, Ajai Chari, Lisa O’Rourke, Kaida Wu, Jordan M. Schecter, Tineke Casneuf, Christopher Chiu, David Soong, A. Kate Sasser, Nushmia Z. Khokhar, Hervé Avet-Loiseau, Saad Z. Usmani   +32 more
doaj   +7 more sources

Lenalidomide-Associated ITP [PDF]

Case Reports in Hematology, 2011
Lenalidomide is a potent immunomodulatory agent being used increasingly for treatment of hematologic malignancies including multiple myeloma and myelodysplasia.
Christina I. Herold, Cristina Gasparetto, Gowthami M. Arepally   +2 more
doaj   +2 more sources

Lenalidomide in Diffuse Large B-Cell Lymphomas [PDF]

Advances in Hematology, 2012
Diffuse Large B-cell Lymphomas (DLBCL) are the most frequent Non-Hodgkin Lymphomas (NHL). The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients, but so far 40% of patients experienced relapse or progressive ...
Annalisa Chiappella, Umberto Vitolo
doaj   +2 more sources

Myeloma-Associated Sporadic Late-Onset Nemaline Myopathy, Successfully Treated with Daratumumab Based Induction and Autologous Stem Cell Transplantation: A Case Report. [PDF]

EJHaem
ABSTRACT Sporadic late‐onset nemaline myopathy (SLONM) is a rare, acquired myopathy often associated with monoclonal gammopathy. We report a 48‐year‐old man presenting with progressive proximal and truncal muscle weakness in whom SLONM associated with smoldering myeloma was highly suspected.
Moriwaki K, Kawano Y, Nakajima M, Nishimura N, Ueda M, Yasunaga JI.   +5 more
europepmc   +2 more sources

Lenalidomide stabilizes protein-protein complexes by turning labile intermolecular H-bonds into robust interactions [PDF]

, 2022
Targeted protein degradation (TPD) is emerging as a very promising strategy to modulate protein activities in several diseases, spearheaded by anti–myeloma drugs lenalidomide and pomalidomide.
Jordi, Juárez-Jiménez, Xavier , Barril, Andrea, Bertran-Mostazo, Jorge, Duro, Marina, Miñarro-Lleonar   +4 more
core   +2 more sources

Bioequivalence study between two formulations of 10mg lenalidomide capsules in healthy male subjects under fasting conditions

, 2023
OBJECTIVE: To evaluate pharmaceutical bioequivalence between two formulations of 10mg lenalidomide capsules in healthy male subjects under fasting conditions.
Vinicius Marcondes Rezende, Ligia de Cassia Val, Murali Pendela, Nelly Cristina Castro, Maria Elena Cedano Limón, Mohammad H. Badii, Carlos Sverdloff, Lygia Bonnato, Sreekanth Kakarla   +8 more
core   +1 more source

Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). [PDF]

, 2019
The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide-dexamethasone can overcome lenalidomide resistance in lenalidomide ...
Hitz, F, Stüdeli, S, Pabst, Thomas, Kraus, M, Mey, U, Hess, D, Rondeau, S, Samaras, P, Besse, L, Seipel, Katja, Driessen, C, Vilei, S Berardi, Silzle, T, Novak, Urban   +13 more
core   +2 more sources

Lenalidomide-Associated Oral Pigmentation: A Case Report. [PDF]

Head Neck Pathol
Background Lenalidomide is an immunomodulatory agent widely used in the treatment of multiple myeloma and is generally associated with a favorable safety profile. Although pigmentary alterations such as cutaneous hyperpigmentation and
de Freitas ALS, de Sousa FGCP, Soares CT, de Souza Giuliani RR, Soares AB.   +4 more
europepmc   +2 more sources

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date

, 2021
Umut Yilmaz, Ayse Salihoglu, Teoman Soysal Division of Hematology, Department of Internal Medicine, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Istanbul, TurkeyCorrespondence: Umut YilmazIstanbul University-Cerrahpasa, Cerrahpasa ...
SALİHOĞLU, Ayşe, Soysal, Teoman, Soysal T, Salihoglu A, Yilmaz U, YILMAZ, Umut   +5 more
core   +1 more source

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/ Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis

, 2022
Purpose: New therapeutic options are needed in relapsed/refrac tory diffuse large B-cell lymphoma (R/R DLBCL). Lenalidomide based schedules can reverse rituximab refractoriness in lymphoma.
Sánchez Margalet, Víctor, Ríos Herranz, Eduardo, Jiménez Cortegana, Carlos, Nogales-Fernández, Esteban, Palazón Carrión, Natalia, Carnicero-González, Fernando, Rueda Domínguez, Antonio, Martín García-Sancho, Alejandro, Cruz Merino, Luis de la   +8 more
core   +1 more source